FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients

BMC Urology

Table 5 Multivariate Cox regression analysis for relapse-free survival in non-invasive high-grade and invasive bladder urothelial carcinomas

	RFS
	HR (95% CI)	p
Model 1^a
TNM stage, Stage 0	1	0.067
Stage I	1.075 (0.423–2.729)	0.88
Stage II, III	1.983 (0.77–5.106)	0.156
Stage IV	0.906 (0.105–7.837)	0.929
FAM83H positive (vs. negative)	3.691 (1.977–6.889)	< 0.001
Model 2^b
TNM stage, Stage 0	1	0.037
Stage I	1.175 (0.871–3.021)	0.738
Stage II, III	2.305 (0.871–6.1)	0.093
Stage IV	1.106 (0.128–9.584)	0.927
Combined expression, FAM83H−/Nectin1−	1	< 0.001
FAM83H−/Nectin1+ or FAM83H+/Nectin1−	3.877 (1.582–9.502)	0.003
FAM83H+/Nectin1+	5.272 (2.377–11.693)	< 0.001

RFS relapse free survival, HR hazard ratio, 95% CI 95% confidence interval
^aVariables considered in model 1 were histologic grade, T stage, N stage, TNM stage, FAM83H expression, and Nectin1 expression
^bVariables considered in model 2 were histologic grade, T stage, N stage, TNM stage, and combined expression of FAM83H and Nectin1

ISSN: 1471-2490